The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Celsion is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Celsion is a member of our Medical group, which includes 847 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CLSN is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for CLSN's full-year earnings has moved 17.02% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, CLSN has gained about 60.99% so far this year. At the same time, Medical stocks have gained an average of 3.33%. This means that Celsion is performing better than its sector in terms of year-to-date returns.
To break things down more, CLSN belongs to the Medical - Biomedical and Genetics industry, a group that includes 353 individual companies and currently sits at #64 in the Zacks Industry Rank. This group has gained an average of 4.76% so far this year, so CLSN is performing better in this area.
Investors in the Medical sector will want to keep a close eye on CLSN as it attempts to continue its solid performance.
Image: Bigstock
Is Celsion (CLSN) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Celsion is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Celsion is a member of our Medical group, which includes 847 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CLSN is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for CLSN's full-year earnings has moved 17.02% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, CLSN has gained about 60.99% so far this year. At the same time, Medical stocks have gained an average of 3.33%. This means that Celsion is performing better than its sector in terms of year-to-date returns.
To break things down more, CLSN belongs to the Medical - Biomedical and Genetics industry, a group that includes 353 individual companies and currently sits at #64 in the Zacks Industry Rank. This group has gained an average of 4.76% so far this year, so CLSN is performing better in this area.
Investors in the Medical sector will want to keep a close eye on CLSN as it attempts to continue its solid performance.